2 terminated. 2 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 2 |
| Phase 1 | 1 | Terminated 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Part 1: new trials by email Literature Review of Part 1 trials Research Report on Part 1
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Study of Liposomal Mitoxantrone Hydrochloride Injection Combined With Pegaspargase in the Treatment of NKTCL Part 1: Liposomal mitoxantrone hydrochloride and Pegaspargase, Part 2 (treatment-naïve patients): Liposomal mitoxantrone hydrochloride and Pegaspargase, Part 2 (relapsed or refractory patients): Liposomal mitoxantrone hydrochloride and Pegaspargase - Extranodal NK/T-cell Lymphoma, Nasal Type | Phase 1 / Phase 2 | Terminated | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 41 | 2020-09-15 | 2024-03-07 |
| Efficacy and Safety of DWJ1248 in Patients With Mild to Moderate COVID-19 Compared to the Placebo Part 1, Part 2 - Mild to Moderate COVID-19 | Phase 2 / Phase 3 | Terminated | Daewoong Pharmaceutical Co. LTD. | 432 | 2020-09-11 | 2022-06-15 |
Lymphoma, Extranodal NK-T-Cell (1)
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (1) · Daewoong Pharmaceutical Co. LTD. (1)
China (1) · South Korea (1)
Ping Liu (1)